Navigation Links
Agendia BV Appoints Mr. Hessel Lindenbergh as Chairman of its Supervisory Board
Date:9/13/2007

AMSTERDAM, September 13 /PRNewswire/ -- Agendia BV, a world leader in the rapidly evolving field of cancer molecular diagnostics, announced today that it has appointed Hessel J. H. M. Lindenbergh as Chairman of its Supervisory Board.

Hessel Lindenbergh is a former member of the managing board of ING Group N.V.. Currently, Mr. Lindenbergh is chairman of the supervisory board of NIB Capital N.V. and board member of the Royal Numico, Petroplus International and Gamma Holding. Mr. Lindenbergh is also a member of the board of directors of the University of Amsterdam (UvA) and Senior Counsel at the Boer & Croon.

Agendia's other supervisory board directors are Prof. Dr. Wim van Harten from the Netherland's Cancer Institute (NKI), Pieter van der Meer from Gilde Health Care, Gertjan van der Baan from van Herk Biotech B.V., and Dr. Gosse Bruisma, an independent member.

In making this announcement, Agendia's CEO, Dr. Bernhard Sixt, stated: "We are very pleased that Mr. Hessel Lindenbergh has accepted the chair of the company's Supervisory Board bringing along a tremendous international reputation in the financial business. We are convinced that our Supervisory Board will contribute to further build the company strategically and to accelerate the commercial success of Agendia."

About Agendia

Agendia, located in Amsterdam, the Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first company to commercialize a prognostic test - MammaPrint(R) - that predicts the risk of breast cancer recurrence. Its second microarray product, CupPrint(R)(i), is a diagnostic test to identify the origin of a metastasis in a cancer type called "Cancer of Unknown Primary". Agendia recently also presented its new colon cancer prognosis profile, ColoPrint(R), which is currently undergoing further validation.

Agendia maintains close ties with several leading academic centers to develop state of the art diagnostic tests for cancer. Agendia also offers its expertise to pharma companies focusing on development of highly effective personalized drugs in the area of oncology.

(i) CupPrint(R) is based on a license to the TUA database of AviaraDx

(ii) RNAretain(R) is a trademark of Asuragen Inc.


'/>"/>
SOURCE Agendia BV
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  Eli Lilly and Company (NYSE: ... galcanezumab for the prevention of migraine at the American ... place April 22-28, 2017, in Boston ... at AAN, including safety and patient outcomes data for ... a reduction in monthly migraine headache days among patients ...
(Date:4/20/2017)... , ... April 20, 2017 , ... NetDimensions appoints Bill ... , With over 20 years of experience in the learning technologies industry, Mastin joins ... company within Learning Technologies Group plc (LTG). At LEO, Mastin served as SVP of ...
(Date:4/20/2017)... , ... April 20, 2017 , ... Parallel6™ , ... trials worldwide, announced today that they were named one of the 2017 Top ... the latest developments in the pharmaceutical industry. , “We take pride in honoring Parallel6 ...
(Date:4/20/2017)... Israel , April 20, 2017  BrainStorm Cell ... cell technologies for neurodegenerative diseases, announced today that Chaim ... for Regenerative Medicine,s (ARM) 5 th Annual Cell & ... 09:40 EDT in Boston . ... Medical Officer & Chief Operating Officer, will participate in a ...
Breaking Biology Technology:
(Date:4/24/2017)... April 24, 2017 Janice Kephart ... with  Identity Strategy Partners, LLP (IdSP) , today ... without President Trump,s March 6, 2017 Executive ... , refugee vetting can be instilled with greater confidence, ... now, all refugee applications are suspended by until ...
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
(Date:4/18/2017)... Inc., a global expert in SoC-based imaging and computing solutions, has ... features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® ... be showcased during the upcoming Medtec Japan at Tokyo Big Sight ... Las Vegas Convention Center April 24-27. ... Click here for an image of the ...
Breaking Biology News(10 mins):